Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Hisamitsu Sales Down 3.4% on Price Cuts, Generic Erosion
April 11, 2019
- Diabetes Drug Imeglimin Hits Primary Goal in Japan PIII: Sumitomo, Poxel
April 10, 2019
- Xofluza Most Promoted Drug in January: Anterio
April 10, 2019
- Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines
April 10, 2019
- Medipal’s Subsidiary to Distribute Stemirac in Japan
April 9, 2019
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
- Lixiana Waging Hand-to-Hand Combat with Xarelto in DOAC Market: Encise FY2018 Snapshot
April 8, 2019
- Novartis’ Eylea Challenger Could Reach Filing This Year for 2020 Launch
April 8, 2019
- 5 Industry-Academia Partners Tie Up for Research to Commercialize Renal Regenerative Medicine
April 8, 2019
- Japan Ethical Drug Sales Up 0.2% in February: Crecon
April 8, 2019
- FDA Accepts NDA Resubmission for Parkinson’s Drug Istradefylline: Kyowa Kirin
April 8, 2019
- Janssen Files Darzalex for Combination Therapy for Treatment-Naïve Multiple Myeloma in Japan
April 8, 2019
- FDA Extends Quizartinib Review by 3 Months: Daiichi Sankyo
April 5, 2019
- Cancer Drug Pexidartinib Filed in Europe: Daiichi Sankyo
April 5, 2019
- Clinigen Gets Japan Rights to Intracerebroventricular Form of Hunter Syndrome Drug Idursulfase Beta
April 5, 2019
- Lilly Japan Nets 263 Billion Yen in 2018, Now 6th in Sales Ranking
April 4, 2019
- Cefazolin Generic Shortage Raises Worries of Supply Crunch after G1 LLP Withdrawals
April 4, 2019
- EquMet Becomes Best Seller for Novartis Japan in FY2018
April 4, 2019
- Japan Pharma Market Skids 1.4% in FY2018: Encise
April 4, 2019
- Gilead’s Biktarvy to Make Japan Debut on April 8
April 4, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…